Funding for this research was provided by:
Funding for this research was provided to Inflexxion by Avenue Therapeutics.
Article History
Accepted: 30 September 2020
First Online: 11 November 2020
Declarations
:
: Funding for this research was provided by Avenue Therapeutics.
: TDG and JLG are employees of and SFB is a consultant to Inflexxion, a division of Integrated Behavioral Health. Inflexxion contracts with government agencies as well as multiple pharmaceutical companies that market some of the products included in the study groups evaluated for this article. Although the sponsor was involved in reviewing the content of this article, all data collection, analysis, and ultimate data interpretation were made by the authors without sponsor influence.
: This study uses deidentified data collected during routine clinical workflow, hence it is not human subject research and is exempt from requirements for institutional review board review.
: Not applicable.
: Not applicable.
: The datasets generated and analyzed during the current study are not publicly available as they are proprietary but may be available from the corresponding author upon reasonable request.
: Not applicable.
: JLG designed the study, provided oversight of the data analysis, and drafted the manuscript. TDG assisted with the study design, conducted all analyses, and contributed significantly to the manuscript writing and editing. SFB provided general oversight of the ASI-MV program and made significant contributions to the manuscript. All authors read and approved the final version.